Use of a pharmaceutical composition containing at least one digestive enzyme in artificial feeding
The invention relates to the use of a pharmaceutical composition in combination with a tube food provided for artificial feeding in the treatment of digestive disorders in case of artificial feeding, where the pharmaceutical composition contains or consists of at least one digestive enzyme, preferably a lipase, particularly preferably a bacterial lipase, most preferably burlulipase (INN) in liquid dosage form, wherein the pharmaceutical composition and the tube food are formulated for being administered simultaneously but separately from each other. The pharmaceutical composition can therefore be administered simultaneously and continuously during the administration of the tube food, but separately from it. As a result, the digestive performance of a patient being artificially fed can be enhanced significantly.
1. A method for the treatment of a digestive disorder, comprising administering to a subject in need thereof a pharmaceutical composition in combination with a tube food provided for artificial feeding, wherein the pharmaceutical composition is in liquid dosage form and comprises at least one digestive enzyme, and wherein the pharmaceutical composition and the tube food are administered simultaneously, but separately from each other.
2. The method of claim 1 , wherein the at least one digestive enzyme is a lipase.
3. The method of claim 1 , wherein the at least one digestive enzyme is a bacterial lipase.
4. The method of claim 1 , wherein the pharmaceutical composition and the tube food are formulated to be administered simultaneously, but separately from each other in such a way that they can be supplied by an at least double-lumen tube system, wherein the tube food is supplied to one lumen of the tube system and the pharmaceutical composition in liquid dosage form is supplied to another lumen of the tube system.
5. The method of claim 1 , wherein the liquid dosage form is a solution, a suspension or an emulsion.
6. The method of claim 1 , wherein the tube food is supplied by a tube system, wherein the tube system is selected to be in the form of a tube which ends in the stomach, in the duodenum or in the jejunum.
7. The method of claim 1 , wherein the tube food is supplied by a tube system, wherein:
(a) the tube system is selected from the group consisting of a nasogastric tube, nasointestinal tube, nasoduodenal tube, nasojejunal tube, PEJ tube and a PEG tube, or
(b) the tube system is a tube system having two or more lumens; or
both (a) and (b).
8. The method of claim 4 , wherein the pharmaceutical composition and the tube food are each supplied from a separate container to the respective lumen of the at least double-lumen tube system.
9. The method of claim 4 , wherein the pharmaceutical composition and the tube food are provided in a multi-compartment container in separate compartments and are supplied through separate feed lines to the respective lumen of the at least double-lumen tube system.
10. The method of claim 4 , wherein rates (volume per time) of administration of the pharmaceutical composition and the tube food are individually controllable by separate, individually controllable infusion or pumping systems for each lumen of the at least two-lumen tube system.
11. The method of claim 1 , wherein the pharmaceutical composition further comprises one or more solvents and/or one or more excipients.
12. The method of claim 3 , wherein the bacterial lipase is present in the form of burlulipase (INN).
13. The method of claim 12 , wherein the burlulipase (INN) is present, in the pharmaceutical composition in liquid dosage form in a concentration of 0.0002 mg/ml to 50 mg/ml based on the burlulipase protein.
14. The method of claim 11 , wherein the pharmaceutical composition comprises water as the one or more solvents.